510(k) Summary of Safety and Effectiveness JUN 1 62009. Hip prosthesis

Similar documents
DEC V,(9/azO (c 0 j

Summary of Safety and Effectiveness

JUN 2 6 butt. EkoSonicTM Endovascular System with Rapid Pulse Modulation

October 28, Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS

kok1 UQ 510(k)J Device {Applicant 510(k) Summary (per 21 CFR (c)) OCT Applicant

510(K) SUMMARY. 510(k) Number KOS'00-r

510(k) SUMMARY MANI Needle and Suture Pack MANI, Inc.

February 22, Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169

AW Server 510 (k) Summary of Safety and Effectiveness

February 5, Dear Kristin Pabst,

BMR ~131o-lvleccai Kesearcn Ltd.

Ultimate Concepts Inc.

SECTION 5 BARDEX TEMPERATURE-SENSING FOLEY CATHETER 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION

July 24, Dear Ms. Rhodes:

August 12, Oertli Instrumente AG Ms. Karin Rohr Head of Quality Management & Regulatory Affairs Hafnerwisenstrasse 4 CH 9442 Berneck Switzerland

MViAKIO. V.A hn2 ATTACHMENT I 610(K) SUMMARY. Submitter:

51O(K) SUMMARY: Therapy family of devices.

L~l t l V~! MAY ?

GE Healthcare MAR

May 7, Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413

March 3, Dear Ms. Alice Gong,

0 EC V-,) 133 Lj9a

SUMMARY OF SAFETY AND EFFECTIVENESS for Powered Muscle Stimulator

June 9, Stryker Corporation Garry T. Hayeck, Ph.D. Senior Regulatory Affairs Specialist 2 Pearl Court Allendale, New Jersey 07401

ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate. 510(k) Summary. February 2007

DEC The three components of the Axxent Electronic Brachytherapy System include the Controller, Balloon Applicators-BR and X-ray Source.

Simpler Implant Solutions Inc Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com Telephone Fax K080115

510(k) Summary. Dentsply Implants. April 30, 2013

MAY SECTION VIII. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

Q(K SVJM~jPagelIof 3

January 12, Dear Amy Yang:

August 21, TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

March 20, Dear Mr. Chen:

November 20, Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom

May 5, Dear Mr. Courtney:

510(k) SUMMARY APR Date: 15 th December 2008

(k)Suminary k

sbchoi~kku.edu jeremy~sooil.com DANA Diabecare IlS Insulin Infusion pump Infusion pump Class II

Datrix, Inc NOV Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System

510(K) SUMMARY [as required by section (c)] FLIGHT 60 Ventilator 510(k) Number K IaO?2Z, JUL

Ad-tech Medical Instrument Corporation. Principal Consultant Quality & Regulatory Associates, LLC. 800 Levanger Lane. Stoughton, Wisconsin 53589

University of Texas Medical School at Houston. April 14, 2015

510(k) Summary (c)

Building 6, Suite 300 RyeBrook, NY C-ontact-N~ame: --- William H-. Schofield Director of TeleHealth Operations. Signal,_Radiofrequency

MAR (k) SUMMARY OF SAFETY AND EFFECTIVENESS (21CFR ) 1. DATE PREPARED: 4/21/2008

Section 5-510(k) Summary. This document is provided in the following pages. DEC

September 25, Dear Ms. McCoy:

Lewis Ward L.W. Ward and Associates, Inc Kirkwood Court Boulder, CO

foq8 510(k) Summary fo r PAIRIETEX ~ COMPOSITE Mesh

Dental Morelli Ltda.

RAMSOFT BUG ,-. I"-, --I 2 N Tel: (416) Fax: (416) sales@ramsoftbiz (k) Summary

Brainreader ApS February 4, 2015 C/O Mette Munch QA Consultant Skagenvej 21 Egaa, 8250 DENMARK

April 7, Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)

,11 DSA Cable, transducer and VS3, VS4 electrode, patient connector

JN (k) Summary Device Identification: Device Description:

EM GR.OUF DIPLOMAT. OT39?1 Company Name: (K)SUMMARY Oc. Submission Correspondent. Emergo Group, Inc. Company Address:

Koqo8 go. ER35 ERO-SCAN Pro Hearing Test System. 61 Martin Lane Elk Grove Village, IL Manager of Instrumentation Products

Phoenix Thera-Lase Systems, LLC Ms. Diane Rutherford Ken Block Consulting 1201 Richardson Drive, Suite 280 Richardson, Texas 75080

Fresenius Medical Care

Manufacturing Technology, Inc.

510(k) SUMMARY. OPTION-vyM Urinary Catheter

ELASTO-GEL MANIJKAH"O"NEY JUUjj 2. fudbthsarltvl of the wound fluid, while re~leas'ing

510(k) Summary. Atlanti STM Abutment and AtlantisTM Crown Abutment in Zirconia for Dentsply Ankylos Implant

DICOM Grid, Inc. January 25, Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

ItP. Section I. 510(k) Summary of Safety and Effectiveness. Applicant:

Food and Drug Administration 5 10(k) Notijfication - Partial & Total Ossicular Replacement Prostheses AUG I June 30, 2006

D I Z1. 510(k) Summary. Section 5. Siemens Medical Solutions USA, Inc. Oncology Care Systems. Date Prepared: September 09,

OCT 18 20U5Ibko. a. Submitter Name: Cosmetic Dental Materials Inc. (CDM Inc.) b. Submitter Address: 812 Water St. NE Albany OR 97321

October 29, Dear Ms. Hartnett:

510(k) Summary GlobalMedia Group, LIC. MAY CONiM

November 17, Nanova Biomaterials, Inc. Mr. Andrew Ritts Senior Research Scientist 3806 Mojave Ct Columbia, Missouri, 65202

KIZ 2,33-3 p8 ~ 510(k) Summary. As required by 21 CFR (c) 510(k) Premarket Notification Submission AFrame Digital MobileCare Monitor.

Ni Hau Industrial Co., Ltd. Ms. Lyn Chiu Sales Manager No. 15, Alley 125, Lane 318, Section 2, An Ho Road Tainan City, Taiwan 70967

AgaMatrucx. NV2 21 Salem, NH oz (k) Sumnmary

May 22, Rachel s Remedies, LLC Mrs. Rachel E. Jackson 2316 Delaware Ave. #174 Buffalo, New York 14216

510(K) Summary K102148

May 20, Ivoclar Vivadent Ag Ms. Donna Hartnett Director Regulatory Affairs Ivoclar Vivadent, Inc. 175 Pineview Drive Amherst, New York 14228

July 21, Dentca, Inc. c/o Mr. Claude Berthoin Denterprise International, Inc. 110 East Granada Blvd, Suite 207 Ormond Beach, Florida 32176

Dear Ms. Lucas: This letter corrects our substantially equivalent letter of February 18, 2016.

MAY Attachment (k) Summary 21 CER

March 31, Etiometry, Inc. Richard Galgon Independent Consulting Associate Quintiles 5846 Cobblestone Lane Waunakee, Wisconsin 53597

March 23, Vision Quest Industries, Inc. Mr. Mohammed Ouerghi Director of QA/RA 1390 Decision Street, Suite A Vista, CA 92081

I C 5 5l v ri 510(K) SUMMARY. Prowess Panther

r5 73~ 9/ / 510(K) Summary (K) SUMMARY

510(k) SUMMARY JUL Otoharmonics 0 Levo 9 System

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

510(k) Summary Special Premarket Notification 510(k) Section 6

DHCPL_RA EXT Page 1 of 6

Section (K) Summary. Kimberly-Clark Corporation Winchester Road Neenah, WI 54956

Metal-on-Metal Hip Systems

Transcription:

V)O9pttot L~~(g 510(k) Summary of Safety and Effectiveness JUN 1 62009 Proprietary Name: Common Name: Rejuvenate Monolithic Size 4 Hip Stem Hip prosthesis Classification Name and Reference: Hip joint metal/ceramic/polymner semi-constrained cemented or nonporous uncemented prosthesis, 21 CFR 888.3353 Hip joint metal/polymer/metal semi-constrained porous coated uncemented prosthesis, 21 CFR 888.3358 Hip joint metal/polymer semi-constrained cemented prosthesis 21 CFR 888.3350 Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis. 21 CFR 888.3390 Hip joint metal/polymer constrained cemented or uncenmented prosthesis. 21 CFR 888.3 31 0 Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis. 21 CFR 888.3360 Regulatory Class: Product Codes: Class II 87 MEH - prosthesis, hip, semi-constrained, uncernented, metal/polymer, non-porous, calciumphosphate 87 LZO - prosthesis, hip, semi-constrained, metal/ceramic/polymer, cemented or non-porous, uncemented 87 LPH - prosthesis, hip, semi-constrained, metal/polymer, porous uncemented 87 JDI - prosthesis, hip, semi-constrained, metal/polymer, cemented 87 KWY - prosthesis, hip, hemi-, femoral, metal/polymer, cemented or uncemented 5

87 KWZ - prosthesis, hip, constrained, cemented or uncemented, metal/polymer 87 KWL - prosthesis, hip, hemi-, femoral, metal 87 LWJ - prosthesis, hip, semi-constrained, metal/polymer, uncemented For Information contact: Estela Celi, Regulatory Affairs Associate Howmedica Osteonics Corp. 325 Corporate Drive Mahwah, NJ 07430 Phone: (201) 831-6461 Fax: (201) 831-3461 Date Prepared: April 20, 2009 Description: The Rejuvenate Monolithic Size 4 Hip stem is part of the previously cleared Rejuvenate Monolithic Hip System. The size 4 monolithic hip stem is intended for cementless, press-fit application. It is designed for use with the available compatible Howmedica Osteonics' femoral heads, bipolars and their compatible acetabular components. Intended Use: The Rejuvenate Monolithic size 4 Hip Stem is a sterile, single-use device intended for use in primary and revision total hip arthroplasty to alleviate pain and restore function. This device is intended to be used with any currently available compatible Howmedica Osteonics acetabular components; V40 femoral heads, V40 Alumina Heads, C-Taper Alumina heads when used with the V40/C-Taper Adaptor and the Biolox Delta Universal Taper Heads and sleeves. Indications: The indications for use of total hip replacement prostheses include: 1) Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis; 2) Rheumatoid arthritis; 3) Correction of functional deformity; 4) Revision procedures where other treatments or devices have failed; and, 5) Treatment of nonunion, femoral neck and trochanteric fractures of the proximal femur with head involvement that is unmanageable using other techniques. 6) Stryker's Rejuvenate Hip System is intended for cementless use only. 6

14oq/111 (p~5 1 Substantial Equivalence: The Rejuvenate Monolithic Hip Size 4 Hip Stem is identical to the stems which are part of the previously submitted Rejuvenate Monolithic Hip System in regard to intended use, design, materials, mechanical testing and operational principles as a hip prosthesis.

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Howmedica Osteonics Corp. % Ms. Estela Celi Regulatory Affairs Associate JUN 1 6 2009 325 Corporate Dr. Mahwah, New Jersey 07430 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Re: K091161 Trade/Device Name: Rejuvenate Monolithic Size 4 Hip Stem Regulation Number: 21 CFR 888.3353 Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis Regulatory Class: Class II Product Code: MEH, LZO, LPH, JDI, KWY, KWZ, KWL, LWJ Dated: April 20, 2009 Received: April 21, 2009 Dear Ms. Celi: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Ms. Estela Celi This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda. gov/cdrh/industr /support/index.html. Sincerely yours, Enclosure Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Indications for Use 510(k)Number(ifknown): j(0 [(([ (PC) I/ Device Name: Rejuvenate Monolithic Size 4 Hip Stem Indications for Use: The indications for use of the total hip replacement prostheses include: 1) Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis; 2) Rheumatoid arthritis 3) Correction of functional deformity; 4) Revision procedures where other treatments or devices have failed; and, 5) Treatment of nonunion, femoral neck and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques. 6) Stryker's Rejuvenate Hip System is intended for cementless use only. Prescription Use X Over-The-Counter Use AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) A~)?,lif ~..:irgca. ~ :... Or.o:e:c -r~, SI 0(k) Numlr 4